Revvity (NYSE:RVTY) Upgraded by Zacks Research to “Hold” Rating

Revvity (NYSE:RVTY) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other analysts also recently issued reports on RVTY. Robert W. Baird set a $117.00 price objective on Revvity in a research note on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Sanford C. Bernstein started coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price for the company. Evercore restated an “outperform” rating on shares of Revvity in a research report on Wednesday. Finally, Stifel Nicolaus reduced their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, Revvity has a consensus rating of “Hold” and an average target price of $108.36.

Revvity Trading Up 3.4%

Shares of RVTY stock opened at $115.19 on Tuesday. Revvity has a 12-month low of $81.22 and a 12-month high of $118.30. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average price is $107.53 and its 200-day moving average price is $99.91. The stock has a market capitalization of $12.85 billion, a price-to-earnings ratio of 54.85, a price-to-earnings-growth ratio of 2.15 and a beta of 1.07.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company had revenue of $711.00 million for the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the business earned $1.18 earnings per share. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts predict that Revvity will post 5.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Revvity

Institutional investors have recently modified their holdings of the stock. Ascentis Independent Advisors bought a new position in shares of Revvity during the 1st quarter valued at approximately $29,000. CYBER HORNET ETFs LLC purchased a new stake in Revvity during the 2nd quarter valued at $32,000. MUFG Securities EMEA plc purchased a new stake in Revvity during the 2nd quarter valued at $34,000. Headlands Technologies LLC bought a new stake in Revvity in the second quarter worth $49,000. Finally, SJS Investment Consulting Inc. lifted its position in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after buying an additional 521 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q2 results exceeded expectations: Revvity reported adjusted earnings of $1.41 per share, above the $1.21–$1.23 consensus range, while revenue of $711 million topped estimates of approximately $703 million. EPS also increased from $1.18 in the prior-year quarter. Revvity raises annual profit, revenue forecasts on strong diagnostics demand
• Positive Sentiment: Full-year guidance was raised: The company now expects 2026 adjusted EPS of $5.30–$5.40, ahead of the $5.25 analyst consensus, and revenue of $2.8–$2.9 billion. Management cited strong diagnostics demand, wider margins and solid cash flow. RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, 2026 View Up
• Positive Sentiment: Growth drivers are improving: Reports highlighted sustained demand for diagnostic testing and renewed interest in drug-development tools. AI-related applications and diagnostics growth are viewed as supporting Revvity’s longer-term outlook. RVTY Q2 deep dive: AI-driven demand and diagnostics growth shape outlook
• Neutral Sentiment: RVTY is trading near its 52-week high and above both its 50-day and 200-day moving averages, indicating strong momentum, although its elevated valuation leaves less room for execution disappointments.
• Negative Sentiment: Quarterly revenue still declined 1.3% year over year, showing that the broader recovery remains uneven despite the earnings beat and upgraded outlook.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.